Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 17, 2023

Anti-CD20 Therapies and COVID-19 Severity in Patients With Relapsing–Remitting and Progressive MS

JAMA Network Open


Additional Info

JAMA Network Open
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
JAMA Netw Open 2023 Jun 01;6(6)e2319766, E Januel, D Hajage, P Labauge, E Maillart, J De Sèze, H Zephir, J Pelletier, L Guilloton, C Bensa, O Heinzlef, O Casez, D Biotti, B Bourre, S Vukusic, A Maurousset, E Berger, D Laplaud, C Lebrun-Frénay, AL Dubessy, P Branger, E Thouvenot, P Clavelou, F Sellal, E Manchon, T Moreau, C Papeix, F Tubach, C Louapre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading